Analysis: Film-Maker Fujifilm To Enter Japan Drug Business with Toyama Chemical Acquisition
This article was originally published in PharmAsia News
Fujifilm Holdings' bid to buy Toyama Chemical signals a move by companies with technologies beneficial to drug making to enter the pharmaceutical market. Ajinomoto, in the seasoning and food business, relies on fermentation technologies for its amino acid-based drugs, and Toray Industries applies biotechnology and nanotechnology to help develop drugs with long-lasting effects. Japan Pharmaceutical Manufacturers Association President Hatsuo Aoki said his industry expects to see an increase in mergers and acquisitions centered on certain technologies rather than company size. (Click here for more - a subscription may be required
You may also be interested in...
TOKYO - Fujifilm Holding's tender offer for Japanese pharma Toyama Chemical started as scheduled on Feb. 19 and will last for one month. In a move that took many in the business industry by surprise, the top global photographic and imaging company declared its intent to move into the pharmaceutical business in a joint announcement with Toyama Chemical and Taisho Pharmaceutical, the top over-the-counter drug company in Japan and major shareholder of Toyama Chemical
Tokyo-based Taisho Pharmaceutical will take its first steps into the lactic acid bacteria drugs market following its proposed acquisition of Kobe, Japan-based Biofermin Pharmaceutical, approved by the latter's board Feb. 12
Announcing his “first step to take on pricing of generic drugs,” billionaire Mark Cuban recently associated his name with a new US generics company “to show that capitalism can be compassionate.” In an exclusive chat with Generics Bulletin, the newly established company’s CEO Alex Oshmyansky revealed that they started working on the company “in stealth” since 2018.